• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.

作者信息

Jones D, Woyach J A, Zhao W, Caruthers S, Tu H, Coleman J, Byrd J C, Johnson A J, Lozanski G

机构信息

Department of Pathology, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.

Division of Hematology, Department of Internal Medicine, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.

出版信息

Leukemia. 2017 Jul;31(7):1645-1647. doi: 10.1038/leu.2017.110. Epub 2017 Apr 3.

DOI:10.1038/leu.2017.110
PMID:28366935
Abstract
摘要

相似文献

1
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.在接受依鲁替尼治疗的慢性淋巴细胞白血病中，PLCG2 C2结构域突变与BTK及PLCG2耐药突变同时出现。
Leukemia. 2017 Jul;31(7):1645-1647. doi: 10.1038/leu.2017.110. Epub 2017 Apr 3.
2
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.在依鲁替尼耐药的慢性淋巴细胞白血病中获得的磷脂酶Cγ2的超形态突变赋予B细胞受体激活对布鲁顿酪氨酸激酶的独立性。
Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13.
3
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?BTK 和 PLCG2 突变是否是慢性淋巴细胞白血病对伊布替尼耐药的必要和充分条件？
Expert Rev Hematol. 2018 Mar;11(3):185-194. doi: 10.1080/17474086.2018.1435268. Epub 2018 Feb 12.
4
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.伊布替尼治疗中断的病因及慢性淋巴细胞白血病患者的结局。
JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.
5
Prevalence of and mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.真实世界 CLL 队列中伊布替尼治疗 3 年后仍存在 和 突变的流行率：一项 FILO 研究。
Blood. 2019 Aug 15;134(7):641-644. doi: 10.1182/blood.2019000854. Epub 2019 Jun 26.
6
BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶介导的慢性淋巴细胞白血病对依鲁替尼的耐药性
J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.
7
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.伊布替尼的布鲁顿酪氨酸激酶抑制剂耐药机制。
N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.
8
Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.解析慢性淋巴细胞白血病中依鲁替尼耐药性
J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14.
9
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.鉴定一种结构新颖的BTK突变，该突变导致慢性淋巴细胞白血病（CLL）对依鲁替尼产生耐药性。
Oncotarget. 2016 Oct 18;7(42):68833-68841. doi: 10.18632/oncotarget.11932.
10
Targeted therapies: ibrutinib resonates with us.靶向疗法：依鲁替尼引起了我们的共鸣。
Nat Rev Clin Oncol. 2014 Jul;11(7):380. doi: 10.1038/nrclinonc.2014.105. Epub 2014 Jun 17.

引用本文的文献

1
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View.慢性淋巴细胞白血病（CLL）中的布鲁顿酪氨酸激酶（BTK）突变：临床视角
Mediterr J Hematol Infect Dis. 2025 Jul 1;17(1):e2025053. doi: 10.4084/MJHID.2025.053. eCollection 2025.
2
Current and future of targeted therapies against BCR::ABL kinases.针对BCR::ABL激酶的靶向治疗的现状与未来。
J Egypt Natl Canc Inst. 2025 Apr 7;37(1):12. doi: 10.1186/s43046-025-00263-5.
3
The crystal and cryo-EM structures of PLCγ2 reveal dynamic interdomain recognitions in autoinhibition.

本文引用的文献

1
BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶介导的慢性淋巴细胞白血病对依鲁替尼的耐药性
J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.
2
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.导致慢性淋巴细胞白血病对伊布替尼耐药的克隆进化。
Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
3
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
PLCγ2 的晶体和冷冻电镜结构揭示了自身抑制中的结构域动态识别。
Sci Adv. 2024 Nov 29;10(48):eadn6037. doi: 10.1126/sciadv.adn6037.
4
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.靶向治疗的进展：应对B细胞淋巴瘤中对BTK抑制的耐药性
Cancers (Basel). 2024 Oct 10;16(20):3434. doi: 10.3390/cancers16203434.
5
Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病治疗反应与耐药性监测
Cancers (Basel). 2024 May 28;16(11):2049. doi: 10.3390/cancers16112049.
6
T Cells Spatially Regulate B Cell Receptor Signaling in Lymphomas through H3K9me3 Modifications.T细胞通过H3K9me3修饰在空间上调节淋巴瘤中的B细胞受体信号传导。
Adv Healthc Mater. 2025 Feb;14(5):e2401192. doi: 10.1002/adhm.202401192. Epub 2024 Jun 28.
7
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂耐药机制的研究进展。
Int J Mol Sci. 2024 May 11;25(10):5246. doi: 10.3390/ijms25105246.
8
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.在接受阿卡替尼或伊布替尼治疗的慢性淋巴细胞白血病进展的患者中，突变特征。
Blood. 2024 Sep 5;144(10):1061-1068. doi: 10.1182/blood.2023023659.
9
Single nucleotide polymorphisms conferring susceptibility to leukemia and oral mucositis: a multi-center pilot study of patients prior to conditioning therapy for hematopoietic cell transplant.单核苷酸多态性与白血病和口腔黏膜炎易感性的关系：造血干细胞移植预处理患者的多中心先导研究。
Support Care Cancer. 2024 Mar 11;32(4):220. doi: 10.1007/s00520-024-08408-3.
10
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).抵抗耐药性：慢性淋巴细胞白血病（CLL）中 BTK 突变的应对策略。
Genes (Basel). 2023 Dec 6;14(12):2182. doi: 10.3390/genes14122182.
接受硼替佐米和沙利度胺治疗的多发性骨髓瘤患者外周神经病变的预测：一项基于单核苷酸多态性阵列的遗传学研究
Hematol Oncol. 2017 Dec;35(4):746-751. doi: 10.1002/hon.2337. Epub 2016 Sep 8.
4
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.用克服Cys481和Thr474突变的非共价抑制剂对抗Btk突变体。
ACS Chem Biol. 2016 Oct 21;11(10):2897-2907. doi: 10.1021/acschembio.6b00480. Epub 2016 Sep 7.
5
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.慢性淋巴细胞白血病患者对 BTK 抑制产生耐药性后的克隆进化。
Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.
6
Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.浆母细胞性 Richter 转化作为慢性淋巴细胞白血病经 BCR 信号抑制剂治疗后的一种耐药机制。
Br J Haematol. 2017 Apr;177(2):324-328. doi: 10.1111/bjh.14062. Epub 2016 May 15.
7
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.在依鲁替尼耐药的慢性淋巴细胞白血病中获得的磷脂酶Cγ2的超形态突变赋予B细胞受体激活对布鲁顿酪氨酸激酶的独立性。
Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13.
8
Dysfunction of phospholipase Cγ in immune disorders and cancer.磷脂酶 Cγ 在免疫紊乱和癌症中的功能障碍。
Trends Biochem Sci. 2014 Dec;39(12):603-11. doi: 10.1016/j.tibs.2014.09.004. Epub 2014 Oct 30.
9
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.伊布替尼的布鲁顿酪氨酸激酶抑制剂耐药机制。
N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.
10
Ibrutinib resistance in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的依鲁替尼耐药性。
N Engl J Med. 2014 Jun 12;370(24):2352-4. doi: 10.1056/NEJMc1402716. Epub 2014 May 28.